Filing Flows › Health Care › Evommune (EVMN)
Evommune (EVMN) earnings and revenue breakdown
Latest: Q3 2025 · 10-Q filed Dec 11, 2025 · Evommune (EVMN) Q3 2025 earnings results →
Q3 2025 125¢ of every $1 of revenue lost · operating margin -133.3%
Evommune made $10.0M in Q3 2025. Operating margin -133.3%, net loss $12.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Dec 11, 2025.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $10.0M in Q3 2025.
Operating costs exceeded revenue by $13.3M, an operating margin of -133.3%. The quarter ended with a net loss of $12.5M.
Operating cash flow was −$9.6M. Non-cash charges added back $311K of depreciation and amortization and $560K of share-based compensation. Working capital and other items added $2.0M. Capital expenditures of $131K exceeded it, leaving free cash flow of −$9.8M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2025 | 10-Q | Dec 11, 2025 | $10.0M | — | -133.3% | −$12.5M | −$9.6M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Evommune
Evommune, Inc. is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. The Company’s mission is to improve patients’ daily lives and prevent the long-term effects of uncontrolled inflammation that are a consequence of the limitations of existing therapies. To achieve this, Evommune is advancing a portfolio of differentiated product candidates that target key drivers of chronic inflammation. For more information, please visit www.evommune.com and follow us on LinkedIn.
In its own words, from its 8-K, filed Aug 6, 2026.
Evommune against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Operating margin: -133.3% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| EVMN Evommune | Q3 2025 | $10.0M | — | -133.3% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Evommune 10-Q on SEC EDGAR · CIK 2044725 · Pharmaceutical Preparations
13F: who owns EVMN and who is buying
More on EVMN
History
Every quarter: Q3 2025 results